《人工智能輔助宮頸細胞學(xué)診斷技術(shù)的應(yīng)用及質(zhì)量控制專家共識》解讀

[摘 要]2023年12月中國婦幼保健協(xié)會和中國婦幼保健協(xié)會婦女病防治專業(yè)委員會共同發(fā)布了《人工智能輔助宮頸細胞學(xué)診斷技術(shù)的應(yīng)用及質(zhì)量控制專家共識》（以下簡稱《共識》）。本文旨在對《共識》進行解讀，便于相關(guān)專業(yè)人員在工作中進一步理解和實踐。

[關(guān)鍵詞]人工智能；宮頸細胞學(xué)；宮頸癌篩查；應(yīng)用；解讀

Doi：10.3969/j.issn.1673-5293.2024.03.001

[中圖分類號]R173

[文獻標(biāo)識碼]A

[文章編號]1673-5293（2024）03-0001-04

Interpretation of expert consensus on application and quality control of artificial intelligence assisted diagnostic techniques for cervical cytology

ZHANG Xiaosong1，DU Yun2，DONG Yan3，BI Hui1

（1.Department of Obstetrics and Gynecology，Peking University First Hospital，Beijing 100034，China; 2.Department of Cytology，Hebei Tumor Hospital，Hebei Shijiazhuang 050011，China; 3.Artificial intelligence Project Office of Chinese Maternal and Child Health Association，Beijing 100089，China）

[Abstract] In December 2023，Chinese Maternal and Child Health Association and Women’s Disease Prevention and Control Professional Committee of Chinese Maternal and Child Health Association jointly launched “Expert consensus on application and quality control of artificial intelligence assisted diagnostic techniques for cervical cytology”（hereinafter referred to as the “Consensus”）.This article aims to interpret the “Consensus”，facilitating further understanding and implementation for relevant professionals in their work.

[Key words] artificial intelligence;cervical cytology;cervical cancer screening;application;interpretation

宮頸癌是威脅女性健康的主要惡性腫瘤之一，據(jù)統(tǒng)計2020年全球新發(fā)宮頸癌60.4萬例，死亡34.2萬例，中、低收入國家是高發(fā)地區(qū)[1]。（剩余7891字）